Table 2.
Patient characteristics regarding allo-HSCT and disease. Stage of disease is defined as 1 for first complete remission of acute leukemia or non-Hodgkin lymphoma or chronic phase of chronic myeloid leukemia)*
| Characteristics | n = 241 | (%) |
|---|---|---|
| Sex |
||
| female |
95 |
(39) |
| male |
146 |
(61) |
| Disease |
||
| acute leukemia, myelodysplastic syndrome |
127 |
(53) |
| chronic myeloid leukemia |
25 |
(10) |
| Hodgkin´s disease |
6 |
(3) |
| non-Hodgkin lymphoma |
45 |
(19) |
| multiple myeloma |
18 |
(7) |
| myeloproliferative disease |
10 |
(4) |
| other |
10 |
(4) |
| Stage of disease at allogeneic hematopoietic stem cell transplantation (allo-HSCT) |
||
| 1 |
36 |
(15) |
| >1 |
204 |
(85) |
| NA |
1 |
(0) |
| Therapeutic radiation |
||
| yes |
22 |
(9) |
| no |
219 |
(91) |
| Smoker |
||
| yes |
86 |
(36) |
| no |
135 |
(56) |
| NA |
20 |
(8) |
| Pulmonary disease before allo-HSCT |
||
| yes |
57 |
(24) |
| no |
147 |
(61) |
| NA |
37 |
(15) |
| Donor type |
||
| matched related donor |
115 |
(48) |
| matched unrelated donor |
126 |
(52) |
| Treatment related mortality: |
||
| yes |
66 |
(27) |
| no |
175 |
(73) |
| Eastern Cooperative Oncology Group index before allo-HSCT |
||
| 0 |
111 |
(46) |
| 1 |
111 |
(46) |
| 2 |
5 |
(2) |
| Cytomegaly virus reactivation risk |
||
| negative/negative |
93 |
(39) |
| donor negative/recipient positive |
41 |
(17) |
| donor positive/recipient negative |
39 |
(16) |
| positive/positive |
66 |
(27) |
| NA |
2 |
(1) |
| Conditioning regimen |
||
| reduced intensity conditioning |
126 |
(52) |
| myeloablative |
115 |
(48) |
| T-cell depletion (with antithymocyte globulin, Campath or selected peripheral blood stem cells) |
||
| yes |
175 |
(73) |
| no |
66 |
(27) |
| Total body irradiation |
||
| yes |
120 |
(50) |
| no |
121 |
(50) |
| Busulfan |
||
| yes |
9 |
(4) |
| no |
232 |
(96) |
| Stem cell source |
||
| peripheral blood stem cells |
193 |
(80) |
| bone marrow |
48 |
(20) |
| Acute graft-vs-host-disease (GvHD) |
||
| no or stage 1 |
110 |
(46) |
| stage >1 |
120 |
(50) |
| NA |
11 |
(4) |
| Chronic GvHD |
||
| no |
132 |
(55) |
| yes | 109 | (45) |
*Mean patient age: 44.5 years (17-68 years); mean donor age: 40.2 years (13-67 years).